Could a VR AI agent beat a chatbot for treating insomnia?

NCT ID NCT07699042

First seen Jul 13, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study compares two ways of delivering digital cognitive behavioral therapy for insomnia (dCBT-I): one uses a standard app with an AI chatbot, the other uses a virtual reality (VR) environment with an embodied AI agent. Adults with insomnia are randomly assigned to one of the two groups and complete the therapy program. The goal is to see if the VR-enhanced version leads to better sleep outcomes and higher treatment adherence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
digital cognitive behavioral therapy for insomnia (dCBT-I) delivered via virtual reality with an embodied AI agent
What this could lead to
If it works, this could offer a more engaging and effective digital therapy for insomnia, potentially improving sleep without medication.
What could go wrong
This is a relatively small trial comparing two digital approaches, so results may not apply to everyone. The VR component may cause discomfort or be less accessible for some users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 7/F, Sleep Assessment Unit, Shatin Hospital, 33 A Kung Kok Street, Ma On Shan, New Territories

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.